Humana Inc.

Humana Inc. (HUM) Market Cap

Humana Inc. has a market capitalization of $24.74B.

Financials based on reported quarter end 2025-12-31

Price: $205.14

β–² 4.38 (2.18%)

Market Cap: 24.74B

NYSE Β· time unavailable

CEO: James A. Rechtin

Sector: Healthcare

Industry: Medical - Healthcare Plans

IPO Date: 1981-12-31

Website: https://www.humana.com

Humana Inc. (HUM) - Company Information

Market Cap: 24.74B Β· Sector: Healthcare

Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, and home solutions services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2021, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.

Analyst Sentiment

59%
Buy

Based on 27 ratings

Analyst 1Y Forecast: $258.57

Average target (based on 6 sources)

Consensus Price Target

Low

$146

Median

$204

High

$344

Average

$226

Potential Upside: 10.1%

Price & Moving Averages

Loading chart...

πŸ“˜ Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

πŸ“˜ Humana Inc. (HUM) β€” Investment Overview

🧩 Business Model Overview

Humana Inc. stands as a leading health and well-being company, primarily focused on the administration and delivery of health insurance plans and related healthcare services. Its core business centers on comprehensive health insurance products, particularly within the government-sponsored programs segment, including Medicare Advantage, Medicaid, and individual Medicare Prescription Drug Plans. The company also supports employer group plans and specialty offerings such as dental, vision, and wellness programs. Humana serves a diverse customer base, including retirees, individuals, employers, and government agencies, operating across the United States. In addition, Humana leverages partnerships with healthcare providers and operates owned clinics and pharmacy solutions to facilitate integrated care delivery, aiming to improve patient outcomes and support cost efficiency.

πŸ’° Revenue Model & Ecosystem

Humana’s revenue streams are multifaceted, derived from insurance premiums, government contracts, and value-added healthcare services. The predominant share comes from recurring premiums paid by members and government programs, supplemented by administrative fees, pharmacy services, clinic operations, and care management solutions. The ecosystem is underpinned by a blend of direct-to-consumer plans and business-to-business relationships, with additional synergies generated through strategic ventures in primary care delivery, home health, and chronic care management. This integration creates multiple touchpoints with consumers, providers, and payers, reinforcing loyalty and sustained engagement across Humana’s network.

🧠 Competitive Advantages

  • Brand strength: Humana has established national recognition in managed care and senior-focused health plans, reinforcing consumer trust and industry credibility.
  • Switching costs: Members often face barriers in transitioning between plans due to network complexity, care continuity concerns, and the challenges of navigating alternative options, increasing retention.
  • Ecosystem stickiness: The integration of primary care, pharmacy, wellness programs, and digital resources offers a comprehensive suite of services, making it more convenient for members to remain within Humana’s ecosystem.
  • Scale + supply chain leverage: Broad geographic coverage and a large membership base grant Humana substantial negotiating power with medical providers and suppliers, supporting favorable terms and operational efficiencies.

πŸš€ Growth Drivers Ahead

Structural tailwinds such as an aging U.S. population and expanding enrollment in Medicare Advantage create a supportive backdrop for Humana’s long-term growth. The company continues to invest in value-based care models, digital health platforms, and holistic, at-home care offerings, aiming to differentiate its care delivery and member experience. Expansion of primary care clinics, deepening partnerships with health systems, and advancements in technology-enabled population health management are poised to enhance both revenue potential and care quality. Additionally, the evolution of supplemental benefits and the extension into new geographies and demographic segments stand as significant avenues for further scaling.

⚠ Risk Factors to Monitor

Humana operates in a highly regulated environment, subject to evolving healthcare policy and reimbursement rate changes that can affect profitability. The marketplace is intensely competitive, with national peers and emerging healthcare disruptors vying for member share and provider relationships. Margin pressures stem from rising medical costs, regulatory mandates on minimum benefit payout ratios, and the capital requirements of expanding care delivery infrastructure. Technological disruption and cybersecurity concerns present additional operational challenges, while ongoing industry consolidation may reshape competitive dynamics.

πŸ“Š Valuation Perspective

The market generally positions Humana at a relative premium among managed care organizations, reflecting its concentrated leadership in Medicare Advantage and recognized ability to execute on integrated care strategies. Investors often attribute value to Humana’s durable cash flows, scale-driven efficiencies, and differentiated approach to customer engagement. That said, valuation remains sensitive to perceived changes in regulatory risk, margin sustainability, and the durability of its competitive moat versus larger diversified peers and emerging upstarts.

πŸ” Investment Takeaway

Humana embodies a compelling blend of stable, recurring revenues and exposure to secular healthcare growth drivers, underpinned by an expanding ecosystem of value-based, integrated services. The bull case emphasizes Humana’s entrenched market positioning in Medicare Advantage, its ability to innovate care delivery, and potential to capitalize on demographic shifts. In contrast, bear scenarios focus on regulatory uncertainty, heightened competitive threats, and structural cost pressures that could challenge long-term margin expansion. Ultimately, Humana represents an established player with defensible advantages but requires ongoing vigilance around industry change, innovation, and execution risk.


⚠ AI-generated research summary β€” not financial advice. Validate using official filings & independent analysis.

Humana delivered solid 2025 results and guided conservatively for 2026 amid a sizable STARS headwind and rate uncertainty. Strong MA membership growth with improved retention and favorable sales mix is expected to be enterprise-accretive through CenterWell, while MA underwriting margins remain slightly below breakeven after STARS. Management highlighted operational improvements, capital efficiency, and a path to restore top-quartile STARS and stable, compelling MA margins by 2028, but near-term outlook remains constrained by funding dynamics and STARS pressures.

Growth

  • Added ~1,000,000 MA members (~20%) in AEP; retention improved >500 bps YoY
  • Over 70% of new sales were switchers from competitor plans; ~12% from competitor plan exits (below HUM market share)
  • ~70% of new sales on 4+ Star contracts; ~30% were bounce-back members
  • >75% of new sales from higher lifetime value channels (~+10ppt YoY)
  • Expect ~25% individual MA membership growth for full-year 2026
  • Early 2026 indicators (risk scores, pharmacy claims, admits per thousand) in line with expectations

Business Development

  • Medicaid now spans 13 states; Georgia and Texas anticipated to launch next year
  • CenterWell growth expected across Pharmacy, Primary Care, and Home Health from membership gains
  • Expect to announce a strategic acquisition in primary care
  • Aaron Martin joined as President of Medicare Advantage; slated to become President of Insurance upon leadership transition

Financials

  • 2025 adjusted EPS: $17.14 (above initial guidance of ~$16.25)
  • 2025 Insurance segment benefit ratio: 90.4% (slightly better than guidance)
  • 2026 adjusted EPS guidance: at least $9
  • Expect 2026 individual MA pretax margin to double YoY when normalized for STARS (95% 4+ Star assumption)
  • After 2026 STARS headwind, individual MA margins expected slightly below breakeven
  • Net 2026 STARS headwind (individual + group MA) ~$3.5B; ~45% of members on 4+ Star plans for BY26
  • Significant improvement expected in 2026 consolidated operating cost ratio from leverage, cost cuts, and transformation

Capital & Funding

  • Comfortable funding 2026 membership growth; capital and debt-to-cap levels viewed as adequate
  • Capital optimization (legal entities, reinsurance, asset sales, deployment timing) reduced funding needs
  • Despite ~40% premium growth from 2024–2026, statutory capital requirements to rise by <20%
  • Capital efficiency improvements offset >$3B of required capital growth from 2024–2026
  • Plan to fund select small/mid-size strategic M&A with noncore asset sales
  • Debt-to-cap expected to remain largely flat; maintaining credit rating remains a priority

Operations & Strategy

  • Focus on consumer-centric products, sustainable margins, and retention; moved away from loss-leader plans
  • Proactive capacity management to absorb growth; onboarding metrics improved (CTMs down, transactional NPS up, HRA completion up)
  • STARS program on track; aiming to return to top quartile by BY2028; more visibility after hybrid season next quarter
  • Efficiency initiatives: supplier consolidation, early retirement program, expanded outsourcing, process simplification, tech/automation

Market & Outlook

  • Will adapt MA benefits to final CMS rate notice; balancing funding with consumer protection
  • 2026 viewed as a step toward unlocking earnings potential by 2028 and delivering stable, compelling MA margins
  • Enterprise accretion expected in 2026 from membership growth, notably via CenterWell tailwinds

Risks Or Headwinds

  • CMS rate notice uncertainty could pressure benefits and margins
  • Large 2026 STARS-related revenue headwind (~$3.5B) with provider offsets lower than typical
  • Execution risk in scaling operations and transformation/outsourcing initiatives
  • Higher retention and growth on <4 Star contracts dampen near-term MA underwriting margins

Sentiment: CAUTIOUS

Note: This summary was synthesized by AI from the HUM Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Fundamentals Overview

Loading fundamentals overview...

πŸ“Š AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"Humana reported quarterly revenues of $32.515 billion but faced a net loss of $796 million, translating to an EPS of -$6.61. The free cash flow for the previous quarter was $836 million. The balance sheet shows total assets of $48.909 billion against liabilities of $31.172 billion, resulting in equity of $17.737 billion. Year-over-year market performance data is unavailable. The company has a stable dividend history with quarterly payments of $0.885. Humana's revenue stream remains robust; however, the recent net loss raises concerns about operational challenges. Profitability is strained, which is reflected in negative earnings per share. Despite this, free cash flow remains solid, indicating efficient cash management and ongoing liquidity strength. The debt profile includes a net debt of $8.169 billion, which appears manageable given the company's asset base, but warrants close monitoring. Shareholder returns have been primarily through dividends, with no recent stock buybacks. Analyst price targets suggest a cautious outlook but with room for recovery. Overall, Humana needs to address its profitability challenges to enhance investor confidence."

Revenue Growth

Good

Revenue growth remains strong at $32.515 billion for the quarter, demonstrating stability and resilience in sales.

Profitability

Caution

Profitability is challenged by a $796 million net loss and a negative EPS of -$6.61, indicating operational issues.

Cash Flow Quality

Positive

Free cash flow is healthy at $836 million, supporting ongoing dividend payments and maintaining liquidity.

Leverage & Balance Sheet

Neutral

The balance sheet is stable with considerable equity, but net debt of $8.169 billion requires monitoring.

Shareholder Returns

Neutral

Dividends are consistent; however, the lack of buybacks could impact total returns if profitability does not improve.

Analyst Sentiment & Valuation

Fair

Analyst price targets are mixed, with a consensus target of $277.5, indicating potential for recovery but requiring caution.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Loading financial data and tables...
πŸ“

SEC Filings (HUM)

Β© 2026 Stock Market Info β€” Humana Inc. (HUM) Financial Profile